Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
PLoS One ; 14(5): e0215604, 2019.
Article in English | MEDLINE | ID: mdl-31050669

ABSTRACT

AIM: Although the atheroprotective effects of statins and angiotensin II receptor blockers (ARBs) are well-established, little is known about their additive effects, especially during the early period of atherosclerosis. The aim of this study was to investigate whether combination of a statin and an ARB exerts synergistic anti-atherosclerotic effects, and to elucidate the mechanisms of combined effects. METHODS: Atherosclerotic plaques were developed in arteries of 23 rabbits using a high-cholesterol diet (HCD) and intra-arterial balloon inflation. Rabbits received one of five different treatment strategies for 4 weeks: positive control [n = 5, HCD]; negative control [n = 3, regular chow diet]; statin [n = 5, HCD and rosuvastatin 10 mg]; ARB [n = 5, HCD and olmesartan 20 mg]; and combination [n = 5, HCD and statin+ARB]. RESULTS: Histological analysis demonstrated that development of atherosclerotic plaques was inhibited more in combination group than in statin group (P = 0.001). Although macrophage infiltration identified by RAM11 staining was not significantly different between combination and individual treatment groups (31.76±4.84% [combination] vs. 38.11±6.53% [statin; P = 0.35] or 35.14±2.87% [ARB; P = 0.62]), the relative proportion of pro-inflammatory M1-macrophages was significantly lower in combination group than in ARB group (3.20±0.47% vs. 5.20±0.78%, P = 0.02). Furthermore, M2-macrophage polarization was higher in combination group than in statin group (17.70±3.04% vs. 7.86±0.68%, P = 0.001). CONCLUSION: Combination treatment with a statin and an ARB produced synergistic protective effects for atherosclerosis initiation and progression, which may be attributed to modulation of macrophage characteristics in the early period of atherosclerosis.


Subject(s)
Angiotensin Receptor Antagonists/administration & dosage , Atherosclerosis/drug therapy , Imidazoles/administration & dosage , Rosuvastatin Calcium/administration & dosage , Tetrazoles/administration & dosage , Angiotensin Receptor Antagonists/pharmacology , Animals , Atherosclerosis/immunology , Atherosclerosis/prevention & control , Cell Polarity , Disease Models, Animal , Drug Synergism , Imidazoles/pharmacology , Macrophages/metabolism , Male , Mice , RAW 264.7 Cells , Rabbits , Rosuvastatin Calcium/pharmacology , Tetrazoles/pharmacology , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...